Burning Rock Biotech (BNR) Cost of Revenue (2019 - 2025)

Burning Rock Biotech's Cost of Revenue history runs 7 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Cost of Revenue fell 20.86% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $19.1 million (down 10.18% YoY), while the FY2025 annual figure was $23.6 million, down 9.69% from the prior year.
• Cost of Revenue was $4.0 million for Q4 2025 at Burning Rock Biotech, down from $4.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $7.6 million in Q1 2022 to a low of $4.0 million in Q4 2025.
• Historically, Cost of Revenue has averaged $5.7 million across 5 years, with a median of $5.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue surged 66.95% in 2022, then declined 20.86% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $6.6 million in 2021, then retreated by 9.79% to $5.9 million in 2022, then climbed by 1.89% to $6.1 million in 2023, then retreated by 17.15% to $5.0 million in 2024, then decreased by 20.86% to $4.0 million in 2025.
• The last three Cost of Revenue figures came in at $4.0 million (Q4 2025), $4.6 million (Q3 2025), and $5.6 million (Q2 2025), per Business Quant data.